Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (for Zonisamide) Clear all
Completed Phase 2 Interventional

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

NCT00709371
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide SR placebo/ bupropion SR placebo, Zonisamide SR placebo/ bupropion SR 360 mg/day, Zonisamide SR 120 mg/day/ bupropion SR placebo, Zonisamide SR 360 mg/day/ bupropion SR placebo, Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day, Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Fairhope, Alabama • La Jolla, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Sep 25, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)

NCT04774250
View directory record Official record
Conditions
Hearing Loss, Noise-Induced
Interventions
Zonisamide 100Mg Cap, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 25, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional Results available

Zonisamide for Heavy Drinkers With Bipolar Disorder

NCT01566370
View directory record Official record
Conditions
Alcohol Use Disorders, Bipolar Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 25, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional Results available

Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism

NCT00862563
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence, Alcohol Abuse
Interventions
Topiramate, Zonisamide, Levetiracetam, Sugar Pill
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 25, 2026, 1:54 AM EDT
Completed Not applicable Interventional Results available

Zonisamide for Weight Reduction in Obese Adults

NCT00275834
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 25, 2026, 1:54 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

NCT05134857
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 25, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Results available

Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence

NCT01847469
View directory record Official record
Conditions
Alcohol Dependence, Post-Traumatic Stress Disorder (PTSD)
Interventions
Enhanced-Cognitive Processing Therapy-C (E-CPT-C), Zonisamide, Placebo
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 25, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

NCT05205811
View directory record Official record
Conditions
Smoking Cessation
Interventions
Bupropion, Zonisamide, Placebo bupropion, Placebo zonisamide, E-cigarette
Drug · Other
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 25, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Noise-Induced Hearing Loss-Acute Exposure Treatment

NCT04768569
View directory record Official record
Conditions
Hearing Loss, Noise-Induced
Interventions
Zonisamide 100Mg Cap, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 25, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

NCT01713946
View directory record Official record
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 25, 2026, 1:54 AM EDT
Withdrawn Phase 4 Interventional

Zonisamide for Fibromyalgia & Migraine

NCT00259636
View directory record Official record
Conditions
Fibromyalgia, Migraine
Interventions
zonisamide
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2011 · Synced Sep 25, 2026, 1:54 AM EDT
Withdrawn Phase 2 Interventional

Zonisamide Outpatient Study

NCT03376139
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder
Interventions
Zonisamide, Placebo Comparator
Drug
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 25, 2026, 1:54 AM EDT
Completed Phase 3 Interventional

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

NCT00363376
View directory record Official record
Conditions
Weight Gain
Interventions
Zonisamide, olanzapine, Sugar Pill (placebo)
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Sep 25, 2026, 1:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation

NCT01685996
View directory record Official record
Conditions
Nicotine Dependence
Interventions
zonisamide, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 25, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism

NCT02901041
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Zonisamide, Take Control, Placebo (for Zonisamide)
Drug · Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
21 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 25, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

NCT00734435
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
zonisamide SR plus olanzapine, Placebo plus olanzapine
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
National City, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Sep 25, 2026, 1:54 AM EDT
Completed Phase 4 Interventional

Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial

NCT00203450
View directory record Official record
Conditions
Obesity
Interventions
Zonegran, Placebo
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 25, 2026, 1:54 AM EDT